nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimipramine—ABCB1—ovarian cancer	0.377	1	CbGaD
Trimipramine—ABCB1—Topotecan—ovarian cancer	0.0523	0.168	CbGbCtD
Trimipramine—ABCB1—Vinorelbine—ovarian cancer	0.0368	0.119	CbGbCtD
Trimipramine—CYP2D6—Vinorelbine—ovarian cancer	0.0347	0.112	CbGbCtD
Trimipramine—CYP3A4—Topotecan—ovarian cancer	0.0313	0.101	CbGbCtD
Trimipramine—CYP2C9—Paclitaxel—ovarian cancer	0.0267	0.0859	CbGbCtD
Trimipramine—ABCB1—Paclitaxel—ovarian cancer	0.0259	0.0833	CbGbCtD
Trimipramine—CYP3A4—Vinorelbine—ovarian cancer	0.0221	0.0711	CbGbCtD
Trimipramine—ABCB1—Docetaxel—ovarian cancer	0.0187	0.0602	CbGbCtD
Trimipramine—CYP3A4—Paclitaxel—ovarian cancer	0.0155	0.0499	CbGbCtD
Trimipramine—ABCB1—Doxorubicin—ovarian cancer	0.0139	0.0449	CbGbCtD
Trimipramine—CYP2D6—Doxorubicin—ovarian cancer	0.0131	0.0423	CbGbCtD
Trimipramine—CYP3A4—Docetaxel—ovarian cancer	0.0112	0.0361	CbGbCtD
Trimipramine—CYP3A4—Doxorubicin—ovarian cancer	0.00835	0.0269	CbGbCtD
Trimipramine—HTR2A—vein—ovarian cancer	0.00284	0.112	CbGeAlD
Trimipramine—SLC6A2—decidua—ovarian cancer	0.000689	0.0271	CbGeAlD
Trimipramine—Paraesthesia—Melphalan—ovarian cancer	0.000679	0.00284	CcSEcCtD
Trimipramine—ADRA1A—epithelium—ovarian cancer	0.000678	0.0266	CbGeAlD
Trimipramine—Decreased appetite—Topotecan—ovarian cancer	0.000671	0.0028	CcSEcCtD
Trimipramine—Coordination abnormal—Doxorubicin—ovarian cancer	0.000671	0.0028	CcSEcCtD
Trimipramine—HRH1—myometrium—ovarian cancer	0.000669	0.0263	CbGeAlD
Trimipramine—Fatigue—Topotecan—ovarian cancer	0.000665	0.00278	CcSEcCtD
Trimipramine—Dyspepsia—Melphalan—ovarian cancer	0.000665	0.00278	CcSEcCtD
Trimipramine—Constipation—Topotecan—ovarian cancer	0.00066	0.00276	CcSEcCtD
Trimipramine—Decreased appetite—Melphalan—ovarian cancer	0.000657	0.00275	CcSEcCtD
Trimipramine—ADRA2A—myometrium—ovarian cancer	0.000657	0.0258	CbGeAlD
Trimipramine—HTR1D—female reproductive system—ovarian cancer	0.000656	0.0258	CbGeAlD
Trimipramine—Fatigue—Melphalan—ovarian cancer	0.000652	0.00272	CcSEcCtD
Trimipramine—HTR2C—female reproductive system—ovarian cancer	0.000649	0.0255	CbGeAlD
Trimipramine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000646	0.0027	CcSEcCtD
Trimipramine—Tachycardia—Vinorelbine—ovarian cancer	0.000644	0.00269	CcSEcCtD
Trimipramine—Feeling abnormal—Topotecan—ovarian cancer	0.000636	0.00266	CcSEcCtD
Trimipramine—Anorexia—Vinorelbine—ovarian cancer	0.000629	0.00263	CcSEcCtD
Trimipramine—Pancytopenia—Docetaxel—ovarian cancer	0.000629	0.00263	CcSEcCtD
Trimipramine—Asthenia—Chlorambucil—ovarian cancer	0.000622	0.0026	CcSEcCtD
Trimipramine—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000622	0.0026	CcSEcCtD
Trimipramine—Hypotension—Vinorelbine—ovarian cancer	0.000617	0.00258	CcSEcCtD
Trimipramine—SLC6A4—female reproductive system—ovarian cancer	0.000615	0.0242	CbGeAlD
Trimipramine—Pruritus—Chlorambucil—ovarian cancer	0.000613	0.00256	CcSEcCtD
Trimipramine—Urticaria—Topotecan—ovarian cancer	0.000613	0.00256	CcSEcCtD
Trimipramine—Abdominal pain—Topotecan—ovarian cancer	0.00061	0.00255	CcSEcCtD
Trimipramine—Body temperature increased—Topotecan—ovarian cancer	0.00061	0.00255	CcSEcCtD
Trimipramine—SLC6A2—gonad—ovarian cancer	0.000607	0.0238	CbGeAlD
Trimipramine—Weight increased—Docetaxel—ovarian cancer	0.000602	0.00252	CcSEcCtD
Trimipramine—Urticaria—Melphalan—ovarian cancer	0.0006	0.00251	CcSEcCtD
Trimipramine—Diarrhoea—Chlorambucil—ovarian cancer	0.000593	0.00248	CcSEcCtD
Trimipramine—Paraesthesia—Vinorelbine—ovarian cancer	0.000593	0.00248	CcSEcCtD
Trimipramine—Tinnitus—Paclitaxel—ovarian cancer	0.000583	0.00244	CcSEcCtD
Trimipramine—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000582	0.00243	CcSEcCtD
Trimipramine—Flushing—Paclitaxel—ovarian cancer	0.00058	0.00242	CcSEcCtD
Trimipramine—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000579	0.00242	CcSEcCtD
Trimipramine—Myocardial infarction—Docetaxel—ovarian cancer	0.000579	0.00242	CcSEcCtD
Trimipramine—Vascular purpura—Epirubicin—ovarian cancer	0.000577	0.00241	CcSEcCtD
Trimipramine—Jaundice—Docetaxel—ovarian cancer	0.000575	0.0024	CcSEcCtD
Trimipramine—Stomatitis—Docetaxel—ovarian cancer	0.000575	0.0024	CcSEcCtD
Trimipramine—Decreased appetite—Vinorelbine—ovarian cancer	0.000574	0.0024	CcSEcCtD
Trimipramine—Fatigue—Vinorelbine—ovarian cancer	0.000569	0.00238	CcSEcCtD
Trimipramine—Constipation—Vinorelbine—ovarian cancer	0.000565	0.00236	CcSEcCtD
Trimipramine—Arrhythmia—Paclitaxel—ovarian cancer	0.000558	0.00233	CcSEcCtD
Trimipramine—Asthenia—Topotecan—ovarian cancer	0.000554	0.00231	CcSEcCtD
Trimipramine—Alopecia—Paclitaxel—ovarian cancer	0.000552	0.00231	CcSEcCtD
Trimipramine—Vomiting—Chlorambucil—ovarian cancer	0.000551	0.0023	CcSEcCtD
Trimipramine—Agranulocytosis—Docetaxel—ovarian cancer	0.000551	0.0023	CcSEcCtD
Trimipramine—Pruritus—Topotecan—ovarian cancer	0.000546	0.00228	CcSEcCtD
Trimipramine—Feeling abnormal—Vinorelbine—ovarian cancer	0.000544	0.00227	CcSEcCtD
Trimipramine—Asthenia—Melphalan—ovarian cancer	0.000542	0.00227	CcSEcCtD
Trimipramine—SLC6A3—testis—ovarian cancer	0.000542	0.0213	CbGeAlD
Trimipramine—SLC6A2—female reproductive system—ovarian cancer	0.000542	0.0213	CbGeAlD
Trimipramine—HTR2A—embryo—ovarian cancer	0.000537	0.0211	CbGeAlD
Trimipramine—Purpura—Epirubicin—ovarian cancer	0.000536	0.00224	CcSEcCtD
Trimipramine—Pruritus—Melphalan—ovarian cancer	0.000535	0.00223	CcSEcCtD
Trimipramine—Vascular purpura—Doxorubicin—ovarian cancer	0.000534	0.00223	CcSEcCtD
Trimipramine—Dysgeusia—Paclitaxel—ovarian cancer	0.000533	0.00223	CcSEcCtD
Trimipramine—Diarrhoea—Topotecan—ovarian cancer	0.000528	0.00221	CcSEcCtD
Trimipramine—Hypoaesthesia—Docetaxel—ovarian cancer	0.000527	0.0022	CcSEcCtD
Trimipramine—Cerebrovascular accident—Epirubicin—ovarian cancer	0.000527	0.0022	CcSEcCtD
Trimipramine—HRH1—epithelium—ovarian cancer	0.000525	0.0206	CbGeAlD
Trimipramine—Urticaria—Vinorelbine—ovarian cancer	0.000525	0.00219	CcSEcCtD
Trimipramine—Abdominal pain—Vinorelbine—ovarian cancer	0.000522	0.00218	CcSEcCtD
Trimipramine—Body temperature increased—Vinorelbine—ovarian cancer	0.000522	0.00218	CcSEcCtD
Trimipramine—HRH1—uterine cervix—ovarian cancer	0.00052	0.0204	CbGeAlD
Trimipramine—Diarrhoea—Melphalan—ovarian cancer	0.000517	0.00216	CcSEcCtD
Trimipramine—Nausea—Chlorambucil—ovarian cancer	0.000515	0.00215	CcSEcCtD
Trimipramine—Vision blurred—Paclitaxel—ovarian cancer	0.000513	0.00214	CcSEcCtD
Trimipramine—ADRA2A—uterine cervix—ovarian cancer	0.000511	0.0201	CbGeAlD
Trimipramine—Dizziness—Topotecan—ovarian cancer	0.00051	0.00213	CcSEcCtD
Trimipramine—Tremor—Paclitaxel—ovarian cancer	0.00051	0.00213	CcSEcCtD
Trimipramine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000505	0.00211	CcSEcCtD
Trimipramine—Agitation—Paclitaxel—ovarian cancer	0.0005	0.00209	CcSEcCtD
Trimipramine—Purpura—Doxorubicin—ovarian cancer	0.000496	0.00207	CcSEcCtD
Trimipramine—HRH1—decidua—ovarian cancer	0.000496	0.0195	CbGeAlD
Trimipramine—Flushing—Docetaxel—ovarian cancer	0.000492	0.00206	CcSEcCtD
Trimipramine—Vomiting—Topotecan—ovarian cancer	0.000491	0.00205	CcSEcCtD
Trimipramine—Malaise—Paclitaxel—ovarian cancer	0.000491	0.00205	CcSEcCtD
Trimipramine—Cerebrovascular accident—Doxorubicin—ovarian cancer	0.000488	0.00204	CcSEcCtD
Trimipramine—ADRA2A—decidua—ovarian cancer	0.000487	0.0191	CbGeAlD
Trimipramine—Rash—Topotecan—ovarian cancer	0.000487	0.00203	CcSEcCtD
Trimipramine—Dermatitis—Topotecan—ovarian cancer	0.000486	0.00203	CcSEcCtD
Trimipramine—Ataxia—Epirubicin—ovarian cancer	0.000486	0.00203	CcSEcCtD
Trimipramine—Headache—Topotecan—ovarian cancer	0.000484	0.00202	CcSEcCtD
Trimipramine—Palpitations—Paclitaxel—ovarian cancer	0.000481	0.00201	CcSEcCtD
Trimipramine—Vomiting—Melphalan—ovarian cancer	0.000481	0.00201	CcSEcCtD
Trimipramine—Rash—Melphalan—ovarian cancer	0.000477	0.00199	CcSEcCtD
Trimipramine—Dermatitis—Melphalan—ovarian cancer	0.000476	0.00199	CcSEcCtD
Trimipramine—Asthenia—Vinorelbine—ovarian cancer	0.000474	0.00198	CcSEcCtD
Trimipramine—Arrhythmia—Docetaxel—ovarian cancer	0.000473	0.00198	CcSEcCtD
Trimipramine—Convulsion—Paclitaxel—ovarian cancer	0.000471	0.00197	CcSEcCtD
Trimipramine—HRH1—endometrium—ovarian cancer	0.000471	0.0185	CbGeAlD
Trimipramine—Hypertension—Paclitaxel—ovarian cancer	0.00047	0.00196	CcSEcCtD
Trimipramine—Alopecia—Docetaxel—ovarian cancer	0.000468	0.00196	CcSEcCtD
Trimipramine—Pruritus—Vinorelbine—ovarian cancer	0.000467	0.00195	CcSEcCtD
Trimipramine—ADRA2A—endometrium—ovarian cancer	0.000462	0.0182	CbGeAlD
Trimipramine—Anxiety—Paclitaxel—ovarian cancer	0.000462	0.00193	CcSEcCtD
Trimipramine—CYP2C19—vagina—ovarian cancer	0.000461	0.0181	CbGeAlD
Trimipramine—Nausea—Topotecan—ovarian cancer	0.000458	0.00192	CcSEcCtD
Trimipramine—Discomfort—Paclitaxel—ovarian cancer	0.000458	0.00191	CcSEcCtD
Trimipramine—Dry mouth—Paclitaxel—ovarian cancer	0.000453	0.00189	CcSEcCtD
Trimipramine—Diarrhoea—Vinorelbine—ovarian cancer	0.000452	0.00189	CcSEcCtD
Trimipramine—Dysgeusia—Docetaxel—ovarian cancer	0.000452	0.00189	CcSEcCtD
Trimipramine—Ataxia—Doxorubicin—ovarian cancer	0.000449	0.00188	CcSEcCtD
Trimipramine—Nausea—Melphalan—ovarian cancer	0.000449	0.00188	CcSEcCtD
Trimipramine—Confusional state—Paclitaxel—ovarian cancer	0.000448	0.00187	CcSEcCtD
Trimipramine—Oedema—Paclitaxel—ovarian cancer	0.000444	0.00186	CcSEcCtD
Trimipramine—Eosinophilia—Epirubicin—ovarian cancer	0.000442	0.00185	CcSEcCtD
Trimipramine—HTR2A—epithelium—ovarian cancer	0.000438	0.0172	CbGeAlD
Trimipramine—SLC6A2—testis—ovarian cancer	0.000437	0.0172	CbGeAlD
Trimipramine—Dizziness—Vinorelbine—ovarian cancer	0.000437	0.00182	CcSEcCtD
Trimipramine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000435	0.00182	CcSEcCtD
Trimipramine—Tachycardia—Paclitaxel—ovarian cancer	0.000433	0.00181	CcSEcCtD
Trimipramine—ADRA2A—gonad—ovarian cancer	0.000429	0.0169	CbGeAlD
Trimipramine—ADRA2A—uterus—ovarian cancer	0.000426	0.0167	CbGeAlD
Trimipramine—Pancytopenia—Epirubicin—ovarian cancer	0.000424	0.00177	CcSEcCtD
Trimipramine—Anorexia—Paclitaxel—ovarian cancer	0.000423	0.00177	CcSEcCtD
Trimipramine—Vomiting—Vinorelbine—ovarian cancer	0.00042	0.00175	CcSEcCtD
Trimipramine—Rash—Vinorelbine—ovarian cancer	0.000416	0.00174	CcSEcCtD
Trimipramine—Dermatitis—Vinorelbine—ovarian cancer	0.000416	0.00174	CcSEcCtD
Trimipramine—Hypotension—Paclitaxel—ovarian cancer	0.000415	0.00173	CcSEcCtD
Trimipramine—Headache—Vinorelbine—ovarian cancer	0.000414	0.00173	CcSEcCtD
Trimipramine—Pollakiuria—Epirubicin—ovarian cancer	0.000412	0.00172	CcSEcCtD
Trimipramine—Eosinophilia—Doxorubicin—ovarian cancer	0.000409	0.00171	CcSEcCtD
Trimipramine—Palpitations—Docetaxel—ovarian cancer	0.000408	0.0017	CcSEcCtD
Trimipramine—Weight increased—Epirubicin—ovarian cancer	0.000406	0.0017	CcSEcCtD
Trimipramine—Insomnia—Paclitaxel—ovarian cancer	0.000402	0.00168	CcSEcCtD
Trimipramine—Convulsion—Docetaxel—ovarian cancer	0.0004	0.00167	CcSEcCtD
Trimipramine—Paraesthesia—Paclitaxel—ovarian cancer	0.000399	0.00167	CcSEcCtD
Trimipramine—DRD2—testis—ovarian cancer	0.000398	0.0157	CbGeAlD
Trimipramine—Hypertension—Docetaxel—ovarian cancer	0.000398	0.00166	CcSEcCtD
Trimipramine—Drowsiness—Epirubicin—ovarian cancer	0.000398	0.00166	CcSEcCtD
Trimipramine—CYP2C9—female reproductive system—ovarian cancer	0.000395	0.0155	CbGeAlD
Trimipramine—Somnolence—Paclitaxel—ovarian cancer	0.000395	0.00165	CcSEcCtD
Trimipramine—Pancytopenia—Doxorubicin—ovarian cancer	0.000392	0.00164	CcSEcCtD
Trimipramine—Nausea—Vinorelbine—ovarian cancer	0.000392	0.00164	CcSEcCtD
Trimipramine—Dyspepsia—Paclitaxel—ovarian cancer	0.000391	0.00163	CcSEcCtD
Trimipramine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.00039	0.00163	CcSEcCtD
Trimipramine—HRH1—female reproductive system—ovarian cancer	0.00039	0.0153	CbGeAlD
Trimipramine—Stomatitis—Epirubicin—ovarian cancer	0.000388	0.00162	CcSEcCtD
Trimipramine—Jaundice—Epirubicin—ovarian cancer	0.000388	0.00162	CcSEcCtD
Trimipramine—Decreased appetite—Paclitaxel—ovarian cancer	0.000386	0.00161	CcSEcCtD
Trimipramine—Dry mouth—Docetaxel—ovarian cancer	0.000384	0.00161	CcSEcCtD
Trimipramine—ADRA2A—female reproductive system—ovarian cancer	0.000383	0.015	CbGeAlD
Trimipramine—Fatigue—Paclitaxel—ovarian cancer	0.000383	0.0016	CcSEcCtD
Trimipramine—Pollakiuria—Doxorubicin—ovarian cancer	0.000382	0.0016	CcSEcCtD
Trimipramine—Constipation—Paclitaxel—ovarian cancer	0.00038	0.00159	CcSEcCtD
Trimipramine—Confusional state—Docetaxel—ovarian cancer	0.00038	0.00159	CcSEcCtD
Trimipramine—Oedema—Docetaxel—ovarian cancer	0.000376	0.00157	CcSEcCtD
Trimipramine—Weight increased—Doxorubicin—ovarian cancer	0.000376	0.00157	CcSEcCtD
Trimipramine—Agranulocytosis—Epirubicin—ovarian cancer	0.000372	0.00155	CcSEcCtD
Trimipramine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000369	0.00154	CcSEcCtD
Trimipramine—Drowsiness—Doxorubicin—ovarian cancer	0.000368	0.00154	CcSEcCtD
Trimipramine—Tachycardia—Docetaxel—ovarian cancer	0.000367	0.00154	CcSEcCtD
Trimipramine—ABCB1—myometrium—ovarian cancer	0.000366	0.0144	CbGeAlD
Trimipramine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000366	0.00153	CcSEcCtD
Trimipramine—HTR2A—gonad—ovarian cancer	0.000365	0.0143	CbGeAlD
Trimipramine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000361	0.00151	CcSEcCtD
Trimipramine—Jaundice—Doxorubicin—ovarian cancer	0.000359	0.0015	CcSEcCtD
Trimipramine—Stomatitis—Doxorubicin—ovarian cancer	0.000359	0.0015	CcSEcCtD
Trimipramine—Anorexia—Docetaxel—ovarian cancer	0.000359	0.0015	CcSEcCtD
Trimipramine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000356	0.00149	CcSEcCtD
Trimipramine—HRH1—female gonad—ovarian cancer	0.000355	0.0139	CbGeAlD
Trimipramine—Urticaria—Paclitaxel—ovarian cancer	0.000353	0.00147	CcSEcCtD
Trimipramine—HRH1—vagina—ovarian cancer	0.000353	0.0139	CbGeAlD
Trimipramine—ABCB1—embryo—ovarian cancer	0.000352	0.0138	CbGeAlD
Trimipramine—Hypotension—Docetaxel—ovarian cancer	0.000352	0.00147	CcSEcCtD
Trimipramine—Abdominal pain—Paclitaxel—ovarian cancer	0.000351	0.00147	CcSEcCtD
Trimipramine—Body temperature increased—Paclitaxel—ovarian cancer	0.000351	0.00147	CcSEcCtD
Trimipramine—ADRA2A—female gonad—ovarian cancer	0.000349	0.0137	CbGeAlD
Trimipramine—ADRA2A—vagina—ovarian cancer	0.000346	0.0136	CbGeAlD
Trimipramine—Agranulocytosis—Doxorubicin—ovarian cancer	0.000344	0.00144	CcSEcCtD
Trimipramine—Insomnia—Docetaxel—ovarian cancer	0.00034	0.00142	CcSEcCtD
Trimipramine—Paraesthesia—Docetaxel—ovarian cancer	0.000338	0.00141	CcSEcCtD
Trimipramine—Somnolence—Docetaxel—ovarian cancer	0.000335	0.0014	CcSEcCtD
Trimipramine—Tinnitus—Epirubicin—ovarian cancer	0.000333	0.00139	CcSEcCtD
Trimipramine—Flushing—Epirubicin—ovarian cancer	0.000332	0.00139	CcSEcCtD
Trimipramine—Dyspepsia—Docetaxel—ovarian cancer	0.000331	0.00138	CcSEcCtD
Trimipramine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000329	0.00138	CcSEcCtD
Trimipramine—Decreased appetite—Docetaxel—ovarian cancer	0.000327	0.00137	CcSEcCtD
Trimipramine—HTR2A—female reproductive system—ovarian cancer	0.000326	0.0128	CbGeAlD
Trimipramine—Fatigue—Docetaxel—ovarian cancer	0.000325	0.00136	CcSEcCtD
Trimipramine—Constipation—Docetaxel—ovarian cancer	0.000322	0.00135	CcSEcCtD
Trimipramine—Arrhythmia—Epirubicin—ovarian cancer	0.000319	0.00133	CcSEcCtD
Trimipramine—Asthenia—Paclitaxel—ovarian cancer	0.000319	0.00133	CcSEcCtD
Trimipramine—SLC6A2—lymph node—ovarian cancer	0.000317	0.0125	CbGeAlD
Trimipramine—Alopecia—Epirubicin—ovarian cancer	0.000316	0.00132	CcSEcCtD
Trimipramine—HRH1—testis—ovarian cancer	0.000315	0.0124	CbGeAlD
Trimipramine—Pruritus—Paclitaxel—ovarian cancer	0.000314	0.00131	CcSEcCtD
Trimipramine—Feeling abnormal—Docetaxel—ovarian cancer	0.00031	0.0013	CcSEcCtD
Trimipramine—ADRA2A—testis—ovarian cancer	0.000309	0.0121	CbGeAlD
Trimipramine—Tinnitus—Doxorubicin—ovarian cancer	0.000308	0.00129	CcSEcCtD
Trimipramine—Flushing—Doxorubicin—ovarian cancer	0.000307	0.00128	CcSEcCtD
Trimipramine—Dysgeusia—Epirubicin—ovarian cancer	0.000305	0.00127	CcSEcCtD
Trimipramine—Diarrhoea—Paclitaxel—ovarian cancer	0.000304	0.00127	CcSEcCtD
Trimipramine—CYP3A4—female reproductive system—ovarian cancer	0.000302	0.0118	CbGeAlD
Trimipramine—Body temperature increased—Docetaxel—ovarian cancer	0.000298	0.00124	CcSEcCtD
Trimipramine—Abdominal pain—Docetaxel—ovarian cancer	0.000298	0.00124	CcSEcCtD
Trimipramine—CYP2D6—female reproductive system—ovarian cancer	0.000297	0.0117	CbGeAlD
Trimipramine—Arrhythmia—Doxorubicin—ovarian cancer	0.000295	0.00123	CcSEcCtD
Trimipramine—HTR2A—vagina—ovarian cancer	0.000295	0.0116	CbGeAlD
Trimipramine—Dizziness—Paclitaxel—ovarian cancer	0.000294	0.00123	CcSEcCtD
Trimipramine—Vision blurred—Epirubicin—ovarian cancer	0.000293	0.00123	CcSEcCtD
Trimipramine—Alopecia—Doxorubicin—ovarian cancer	0.000292	0.00122	CcSEcCtD
Trimipramine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000289	0.00121	CcSEcCtD
Trimipramine—ABCB1—epithelium—ovarian cancer	0.000287	0.0113	CbGeAlD
Trimipramine—Agitation—Epirubicin—ovarian cancer	0.000286	0.00119	CcSEcCtD
Trimipramine—ABCB1—uterine cervix—ovarian cancer	0.000285	0.0112	CbGeAlD
Trimipramine—Vomiting—Paclitaxel—ovarian cancer	0.000282	0.00118	CcSEcCtD
Trimipramine—Dysgeusia—Doxorubicin—ovarian cancer	0.000282	0.00118	CcSEcCtD
Trimipramine—Malaise—Epirubicin—ovarian cancer	0.000281	0.00117	CcSEcCtD
Trimipramine—Rash—Paclitaxel—ovarian cancer	0.00028	0.00117	CcSEcCtD
Trimipramine—Dermatitis—Paclitaxel—ovarian cancer	0.00028	0.00117	CcSEcCtD
Trimipramine—Headache—Paclitaxel—ovarian cancer	0.000278	0.00116	CcSEcCtD
Trimipramine—Palpitations—Epirubicin—ovarian cancer	0.000275	0.00115	CcSEcCtD
Trimipramine—ABCB1—decidua—ovarian cancer	0.000271	0.0107	CbGeAlD
Trimipramine—Vision blurred—Doxorubicin—ovarian cancer	0.000271	0.00113	CcSEcCtD
Trimipramine—Asthenia—Docetaxel—ovarian cancer	0.00027	0.00113	CcSEcCtD
Trimipramine—CYP2D6—female gonad—ovarian cancer	0.00027	0.0106	CbGeAlD
Trimipramine—Convulsion—Epirubicin—ovarian cancer	0.00027	0.00113	CcSEcCtD
Trimipramine—Hypertension—Epirubicin—ovarian cancer	0.000269	0.00112	CcSEcCtD
Trimipramine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000267	0.00112	CcSEcCtD
Trimipramine—Pruritus—Docetaxel—ovarian cancer	0.000266	0.00111	CcSEcCtD
Trimipramine—Agitation—Doxorubicin—ovarian cancer	0.000265	0.00111	CcSEcCtD
Trimipramine—Anxiety—Epirubicin—ovarian cancer	0.000264	0.0011	CcSEcCtD
Trimipramine—Nausea—Paclitaxel—ovarian cancer	0.000264	0.0011	CcSEcCtD
Trimipramine—HTR2A—testis—ovarian cancer	0.000263	0.0103	CbGeAlD
Trimipramine—Discomfort—Epirubicin—ovarian cancer	0.000262	0.00109	CcSEcCtD
Trimipramine—Malaise—Doxorubicin—ovarian cancer	0.00026	0.00108	CcSEcCtD
Trimipramine—Dry mouth—Epirubicin—ovarian cancer	0.000259	0.00108	CcSEcCtD
Trimipramine—ABCB1—endometrium—ovarian cancer	0.000258	0.0101	CbGeAlD
Trimipramine—Diarrhoea—Docetaxel—ovarian cancer	0.000258	0.00108	CcSEcCtD
Trimipramine—Confusional state—Epirubicin—ovarian cancer	0.000256	0.00107	CcSEcCtD
Trimipramine—Palpitations—Doxorubicin—ovarian cancer	0.000254	0.00106	CcSEcCtD
Trimipramine—Oedema—Epirubicin—ovarian cancer	0.000254	0.00106	CcSEcCtD
Trimipramine—Convulsion—Doxorubicin—ovarian cancer	0.000249	0.00104	CcSEcCtD
Trimipramine—Dizziness—Docetaxel—ovarian cancer	0.000249	0.00104	CcSEcCtD
Trimipramine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000249	0.00104	CcSEcCtD
Trimipramine—Hypertension—Doxorubicin—ovarian cancer	0.000249	0.00104	CcSEcCtD
Trimipramine—Tachycardia—Epirubicin—ovarian cancer	0.000248	0.00104	CcSEcCtD
Trimipramine—Anxiety—Doxorubicin—ovarian cancer	0.000244	0.00102	CcSEcCtD
Trimipramine—Discomfort—Doxorubicin—ovarian cancer	0.000242	0.00101	CcSEcCtD
Trimipramine—Anorexia—Epirubicin—ovarian cancer	0.000242	0.00101	CcSEcCtD
Trimipramine—Dry mouth—Doxorubicin—ovarian cancer	0.00024	0.001	CcSEcCtD
Trimipramine—CYP2D6—testis—ovarian cancer	0.000239	0.00941	CbGeAlD
Trimipramine—Vomiting—Docetaxel—ovarian cancer	0.000239	0.001	CcSEcCtD
Trimipramine—ABCB1—gonad—ovarian cancer	0.000239	0.00939	CbGeAlD
Trimipramine—ABCB1—uterus—ovarian cancer	0.000237	0.00933	CbGeAlD
Trimipramine—Rash—Docetaxel—ovarian cancer	0.000237	0.000992	CcSEcCtD
Trimipramine—Hypotension—Epirubicin—ovarian cancer	0.000237	0.000992	CcSEcCtD
Trimipramine—Dermatitis—Docetaxel—ovarian cancer	0.000237	0.000991	CcSEcCtD
Trimipramine—Confusional state—Doxorubicin—ovarian cancer	0.000237	0.00099	CcSEcCtD
Trimipramine—Headache—Docetaxel—ovarian cancer	0.000236	0.000986	CcSEcCtD
Trimipramine—Oedema—Doxorubicin—ovarian cancer	0.000235	0.000982	CcSEcCtD
Trimipramine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.00023	0.000961	CcSEcCtD
Trimipramine—Insomnia—Epirubicin—ovarian cancer	0.00023	0.00096	CcSEcCtD
Trimipramine—Tachycardia—Doxorubicin—ovarian cancer	0.000229	0.000958	CcSEcCtD
Trimipramine—HRH1—lymph node—ovarian cancer	0.000228	0.00896	CbGeAlD
Trimipramine—Paraesthesia—Epirubicin—ovarian cancer	0.000228	0.000953	CcSEcCtD
Trimipramine—Somnolence—Epirubicin—ovarian cancer	0.000226	0.000943	CcSEcCtD
Trimipramine—ADRA2A—lymph node—ovarian cancer	0.000224	0.0088	CbGeAlD
Trimipramine—Anorexia—Doxorubicin—ovarian cancer	0.000224	0.000936	CcSEcCtD
Trimipramine—Nausea—Docetaxel—ovarian cancer	0.000224	0.000935	CcSEcCtD
Trimipramine—Dyspepsia—Epirubicin—ovarian cancer	0.000223	0.000934	CcSEcCtD
Trimipramine—Decreased appetite—Epirubicin—ovarian cancer	0.000221	0.000922	CcSEcCtD
Trimipramine—Hypotension—Doxorubicin—ovarian cancer	0.00022	0.000918	CcSEcCtD
Trimipramine—Fatigue—Epirubicin—ovarian cancer	0.000219	0.000915	CcSEcCtD
Trimipramine—Constipation—Epirubicin—ovarian cancer	0.000217	0.000907	CcSEcCtD
Trimipramine—ABCB1—female reproductive system—ovarian cancer	0.000213	0.00839	CbGeAlD
Trimipramine—Insomnia—Doxorubicin—ovarian cancer	0.000212	0.000888	CcSEcCtD
Trimipramine—Paraesthesia—Doxorubicin—ovarian cancer	0.000211	0.000882	CcSEcCtD
Trimipramine—Feeling abnormal—Epirubicin—ovarian cancer	0.000209	0.000874	CcSEcCtD
Trimipramine—Somnolence—Doxorubicin—ovarian cancer	0.000209	0.000873	CcSEcCtD
Trimipramine—Dyspepsia—Doxorubicin—ovarian cancer	0.000207	0.000864	CcSEcCtD
Trimipramine—Decreased appetite—Doxorubicin—ovarian cancer	0.000204	0.000854	CcSEcCtD
Trimipramine—Fatigue—Doxorubicin—ovarian cancer	0.000203	0.000847	CcSEcCtD
Trimipramine—Urticaria—Epirubicin—ovarian cancer	0.000202	0.000843	CcSEcCtD
Trimipramine—ABCB1—bone marrow—ovarian cancer	0.000201	0.00792	CbGeAlD
Trimipramine—Constipation—Doxorubicin—ovarian cancer	0.000201	0.00084	CcSEcCtD
Trimipramine—Abdominal pain—Epirubicin—ovarian cancer	0.000201	0.000839	CcSEcCtD
Trimipramine—Body temperature increased—Epirubicin—ovarian cancer	0.000201	0.000839	CcSEcCtD
Trimipramine—ABCB1—female gonad—ovarian cancer	0.000194	0.00763	CbGeAlD
Trimipramine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000194	0.000809	CcSEcCtD
Trimipramine—ABCB1—vagina—ovarian cancer	0.000193	0.00758	CbGeAlD
Trimipramine—Urticaria—Doxorubicin—ovarian cancer	0.000187	0.00078	CcSEcCtD
Trimipramine—Body temperature increased—Doxorubicin—ovarian cancer	0.000186	0.000776	CcSEcCtD
Trimipramine—Abdominal pain—Doxorubicin—ovarian cancer	0.000186	0.000776	CcSEcCtD
Trimipramine—Asthenia—Epirubicin—ovarian cancer	0.000182	0.000761	CcSEcCtD
Trimipramine—Pruritus—Epirubicin—ovarian cancer	0.00018	0.000751	CcSEcCtD
Trimipramine—Diarrhoea—Epirubicin—ovarian cancer	0.000174	0.000726	CcSEcCtD
Trimipramine—ABCB1—testis—ovarian cancer	0.000172	0.00677	CbGeAlD
Trimipramine—Asthenia—Doxorubicin—ovarian cancer	0.000169	0.000704	CcSEcCtD
Trimipramine—Dizziness—Epirubicin—ovarian cancer	0.000168	0.000702	CcSEcCtD
Trimipramine—Pruritus—Doxorubicin—ovarian cancer	0.000166	0.000695	CcSEcCtD
Trimipramine—Vomiting—Epirubicin—ovarian cancer	0.000161	0.000675	CcSEcCtD
Trimipramine—Diarrhoea—Doxorubicin—ovarian cancer	0.000161	0.000672	CcSEcCtD
Trimipramine—Rash—Epirubicin—ovarian cancer	0.00016	0.000669	CcSEcCtD
Trimipramine—Dermatitis—Epirubicin—ovarian cancer	0.00016	0.000668	CcSEcCtD
Trimipramine—Headache—Epirubicin—ovarian cancer	0.000159	0.000665	CcSEcCtD
Trimipramine—Dizziness—Doxorubicin—ovarian cancer	0.000155	0.000649	CcSEcCtD
Trimipramine—Nausea—Epirubicin—ovarian cancer	0.000151	0.00063	CcSEcCtD
Trimipramine—Vomiting—Doxorubicin—ovarian cancer	0.000149	0.000624	CcSEcCtD
Trimipramine—Rash—Doxorubicin—ovarian cancer	0.000148	0.000619	CcSEcCtD
Trimipramine—Dermatitis—Doxorubicin—ovarian cancer	0.000148	0.000619	CcSEcCtD
Trimipramine—Headache—Doxorubicin—ovarian cancer	0.000147	0.000615	CcSEcCtD
Trimipramine—Nausea—Doxorubicin—ovarian cancer	0.00014	0.000583	CcSEcCtD
Trimipramine—ABCB1—lymph node—ovarian cancer	0.000125	0.00491	CbGeAlD
Trimipramine—Epinastine—ABCB1—ovarian cancer	8.26e-05	0.198	CrCbGaD
Trimipramine—Carbamazepine—ABCB1—ovarian cancer	5.19e-05	0.124	CrCbGaD
Trimipramine—Clomipramine—ABCB1—ovarian cancer	4.37e-05	0.105	CrCbGaD
Trimipramine—Promethazine—ABCB1—ovarian cancer	3.87e-05	0.0926	CrCbGaD
Trimipramine—Doxepin—ABCB1—ovarian cancer	3.83e-05	0.0917	CrCbGaD
Trimipramine—Methadone—ABCB1—ovarian cancer	3.81e-05	0.0912	CrCbGaD
Trimipramine—Desipramine—ABCB1—ovarian cancer	3.52e-05	0.0841	CrCbGaD
Trimipramine—Chlorpromazine—ABCB1—ovarian cancer	3e-05	0.0717	CrCbGaD
Trimipramine—Imipramine—ABCB1—ovarian cancer	2.98e-05	0.0714	CrCbGaD
Trimipramine—Amitriptyline—ABCB1—ovarian cancer	2.97e-05	0.0709	CrCbGaD
Trimipramine—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	5.72e-06	0.00012	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	5.72e-06	0.00012	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—IL2—ovarian cancer	5.71e-06	0.00012	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—ERBB2—ovarian cancer	5.71e-06	0.00012	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	5.7e-06	0.00012	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	5.7e-06	0.000119	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	5.69e-06	0.000119	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—CAV1—ovarian cancer	5.68e-06	0.000119	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MMP9—ovarian cancer	5.68e-06	0.000119	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CG—ovarian cancer	5.68e-06	0.000119	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MMP9—ovarian cancer	5.65e-06	0.000118	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—PTEN—ovarian cancer	5.65e-06	0.000118	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MTOR—ovarian cancer	5.64e-06	0.000118	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	5.64e-06	0.000118	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MTOR—ovarian cancer	5.63e-06	0.000118	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PIK3CB—ovarian cancer	5.63e-06	0.000118	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—PTEN—ovarian cancer	5.62e-06	0.000118	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	5.6e-06	0.000117	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	5.57e-06	0.000117	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CG—ovarian cancer	5.54e-06	0.000116	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	5.53e-06	0.000116	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	5.53e-06	0.000116	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	5.52e-06	0.000116	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CXCL8—ovarian cancer	5.51e-06	0.000115	CbGpPWpGaD
Trimipramine—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	5.51e-06	0.000115	CbGpPWpGaD
Trimipramine—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	5.48e-06	0.000115	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—HRAS—ovarian cancer	5.48e-06	0.000115	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.43e-06	0.000114	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	5.42e-06	0.000114	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CXCL8—ovarian cancer	5.41e-06	0.000113	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	5.41e-06	0.000113	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	5.39e-06	0.000113	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	5.38e-06	0.000113	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—HRAS—ovarian cancer	5.38e-06	0.000113	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	5.38e-06	0.000113	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	5.34e-06	0.000112	CbGpPWpGaD
Trimipramine—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	5.32e-06	0.000112	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	5.31e-06	0.000111	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PTEN—ovarian cancer	5.31e-06	0.000111	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	5.3e-06	0.000111	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	5.3e-06	0.000111	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	5.29e-06	0.000111	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	5.28e-06	0.000111	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	5.28e-06	0.000111	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CASP3—ovarian cancer	5.28e-06	0.000111	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—IL2—ovarian cancer	5.27e-06	0.00011	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	5.24e-06	0.00011	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—IL6—ovarian cancer	5.24e-06	0.00011	CbGpPWpGaD
Trimipramine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	5.24e-06	0.00011	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	5.23e-06	0.00011	CbGpPWpGaD
Trimipramine—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	5.23e-06	0.00011	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	5.22e-06	0.000109	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	5.22e-06	0.000109	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	5.2e-06	0.000109	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	5.19e-06	0.000109	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	5.19e-06	0.000109	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—IL2—ovarian cancer	5.18e-06	0.000109	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CASP3—ovarian cancer	5.18e-06	0.000109	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CG—ovarian cancer	5.18e-06	0.000108	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—IL2—ovarian cancer	5.17e-06	0.000108	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—TP53—ovarian cancer	5.17e-06	0.000108	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	5.16e-06	0.000108	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—IL6—ovarian cancer	5.15e-06	0.000108	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CCND1—ovarian cancer	5.14e-06	0.000108	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	5.13e-06	0.000108	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	5.13e-06	0.000108	CbGpPWpGaD
Trimipramine—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	5.13e-06	0.000107	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.1e-06	0.000107	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	5.1e-06	0.000107	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	5.09e-06	0.000107	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	5.08e-06	0.000106	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—IL2—ovarian cancer	5.08e-06	0.000106	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	5.07e-06	0.000106	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	5.05e-06	0.000106	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	5.05e-06	0.000106	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—STAT3—ovarian cancer	5.05e-06	0.000106	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CCND1—ovarian cancer	5.04e-06	0.000106	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—NRAS—ovarian cancer	5.04e-06	0.000106	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	5.02e-06	0.000105	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	5.01e-06	0.000105	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	5e-06	0.000105	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	5e-06	0.000105	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	4.99e-06	0.000105	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CD—ovarian cancer	4.99e-06	0.000105	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MMP9—ovarian cancer	4.99e-06	0.000104	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—PTEN—ovarian cancer	4.96e-06	0.000104	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	4.95e-06	0.000104	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—HRAS—ovarian cancer	4.94e-06	0.000103	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	4.93e-06	0.000103	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	4.91e-06	0.000103	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	4.9e-06	0.000103	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	4.9e-06	0.000103	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MMP9—ovarian cancer	4.89e-06	0.000103	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	4.88e-06	0.000102	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.87e-06	0.000102	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PTEN—ovarian cancer	4.87e-06	0.000102	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MYC—ovarian cancer	4.86e-06	0.000102	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	4.86e-06	0.000102	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	4.84e-06	0.000101	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	4.82e-06	0.000101	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	4.82e-06	0.000101	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	4.81e-06	0.000101	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	4.8e-06	0.000101	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	4.8e-06	0.000101	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	4.8e-06	0.0001	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	4.78e-06	0.0001	CbGpPWpGaD
Trimipramine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	4.77e-06	9.99e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	4.76e-06	9.97e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	4.75e-06	9.96e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	4.75e-06	9.96e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—AKT1—ovarian cancer	4.75e-06	9.95e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.74e-06	9.92e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—IL6—ovarian cancer	4.73e-06	9.91e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	4.72e-06	9.89e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	4.72e-06	9.88e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	4.69e-06	9.83e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MYC—ovarian cancer	4.69e-06	9.83e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MYC—ovarian cancer	4.67e-06	9.78e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	4.66e-06	9.76e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—TYMS—ovarian cancer	4.65e-06	9.75e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	4.6e-06	9.63e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	4.59e-06	9.62e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	4.59e-06	9.62e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	4.59e-06	9.62e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—EGFR—ovarian cancer	4.59e-06	9.61e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	4.57e-06	9.57e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	4.56e-06	9.56e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	4.55e-06	9.54e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CD—ovarian cancer	4.55e-06	9.54e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	4.49e-06	9.41e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	4.48e-06	9.38e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	4.47e-06	9.36e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	4.46e-06	9.35e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	4.44e-06	9.3e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—STAT3—ovarian cancer	4.43e-06	9.29e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—NRAS—ovarian cancer	4.42e-06	9.26e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	4.4e-06	9.23e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—VEGFA—ovarian cancer	4.4e-06	9.21e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	4.37e-06	9.16e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	4.37e-06	9.16e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—AKT1—ovarian cancer	4.36e-06	9.14e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	4.36e-06	9.14e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—STAT3—ovarian cancer	4.35e-06	9.12e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	4.35e-06	9.12e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CB—ovarian cancer	4.35e-06	9.12e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—NRAS—ovarian cancer	4.34e-06	9.1e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—KRAS—ovarian cancer	4.33e-06	9.08e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	4.33e-06	9.07e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	4.31e-06	9.04e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	4.31e-06	9.04e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	4.27e-06	8.95e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	4.26e-06	8.93e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.25e-06	8.9e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	4.23e-06	8.87e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	4.17e-06	8.73e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MAPK3—ovarian cancer	4.16e-06	8.71e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	4.13e-06	8.65e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	4.13e-06	8.64e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MYC—ovarian cancer	4.12e-06	8.63e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	4.08e-06	8.55e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MYC—ovarian cancer	4.05e-06	8.49e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MYC—ovarian cancer	4.04e-06	8.47e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	4.03e-06	8.44e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—EGFR—ovarian cancer	4.03e-06	8.44e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	4.01e-06	8.4e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4e-06	8.38e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—TP53—ovarian cancer	3.99e-06	8.36e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	3.98e-06	8.34e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	3.97e-06	8.31e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	3.97e-06	8.31e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CB—ovarian cancer	3.97e-06	8.31e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	3.96e-06	8.31e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	3.96e-06	8.31e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	3.96e-06	8.3e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	3.96e-06	8.29e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MAPK1—ovarian cancer	3.96e-06	8.29e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—EGFR—ovarian cancer	3.96e-06	8.29e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	3.88e-06	8.13e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	3.88e-06	8.13e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—TP53—ovarian cancer	3.85e-06	8.07e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—TP53—ovarian cancer	3.83e-06	8.03e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	3.82e-06	8e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—KRAS—ovarian cancer	3.81e-06	7.97e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	3.79e-06	7.95e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	3.79e-06	7.94e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PTEN—ovarian cancer	3.76e-06	7.88e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CAV1—ovarian cancer	3.75e-06	7.85e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	3.74e-06	7.85e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	3.74e-06	7.84e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—KRAS—ovarian cancer	3.74e-06	7.83e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	3.69e-06	7.73e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—HRAS—ovarian cancer	3.68e-06	7.72e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PTEN—ovarian cancer	3.67e-06	7.69e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	3.67e-06	7.69e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	3.67e-06	7.68e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	3.67e-06	7.68e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—IL6—ovarian cancer	3.65e-06	7.65e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	3.61e-06	7.56e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	3.61e-06	7.56e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—IL6—ovarian cancer	3.53e-06	7.39e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	3.51e-06	7.35e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—IL6—ovarian cancer	3.51e-06	7.35e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	3.5e-06	7.33e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PTEN—ovarian cancer	3.46e-06	7.24e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	3.44e-06	7.21e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	3.43e-06	7.19e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PTEN—ovarian cancer	3.43e-06	7.18e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.41e-06	7.15e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	3.41e-06	7.14e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—TP53—ovarian cancer	3.38e-06	7.09e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	3.37e-06	7.06e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	3.37e-06	7.06e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	3.36e-06	7.04e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—TP53—ovarian cancer	3.33e-06	6.97e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—TP53—ovarian cancer	3.32e-06	6.96e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	3.26e-06	6.83e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—AKT1—ovarian cancer	3.25e-06	6.82e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	3.24e-06	6.78e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—HRAS—ovarian cancer	3.23e-06	6.78e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	3.18e-06	6.67e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—HRAS—ovarian cancer	3.18e-06	6.65e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	3.13e-06	6.56e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	3.12e-06	6.53e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	3.1e-06	6.49e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—IL6—ovarian cancer	3.1e-06	6.49e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—AKT1—ovarian cancer	3.06e-06	6.41e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—IL6—ovarian cancer	3.05e-06	6.38e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—IL6—ovarian cancer	3.04e-06	6.37e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	3.03e-06	6.34e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3e-06	6.29e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	2.98e-06	6.25e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	2.9e-06	6.07e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—AKT1—ovarian cancer	2.86e-06	5.98e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	2.81e-06	5.89e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—AKT1—ovarian cancer	2.8e-06	5.88e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	2.77e-06	5.81e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	2.75e-06	5.77e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CA—ovarian cancer	2.65e-06	5.56e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.62e-06	5.48e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.59e-06	5.42e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.56e-06	5.36e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.44e-06	5.11e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.42e-06	5.07e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PTEN—ovarian cancer	2.26e-06	4.74e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—AKT1—ovarian cancer	2.17e-06	4.54e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—AKT1—ovarian cancer	2.11e-06	4.43e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—AKT1—ovarian cancer	1.99e-06	4.18e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—AKT1—ovarian cancer	1.98e-06	4.14e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.59e-06	3.34e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—AKT1—ovarian cancer	1.3e-06	2.73e-05	CbGpPWpGaD
